@article{ATM17239,
author = {Kazuto Harada and Dilsa Mizrak Kaya and Anthony Lopez and Hideo Baba and Jaffer A. Ajani},
title = {Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma},
journal = {Annals of Translational Medicine},
volume = {6},
number = {4},
year = {2017},
keywords = {},
abstract = {Preoperative therapy is the gold standard for esophageal or gastroesophageal junction adenocarcinoma. Positron emission tomography (PET) is not only essential for tumor staging, but changes in glucose consumption correspond with response to therapy and correlated with prognosis. Therefore, with further refinement, PET parameter can serve as a tool for personalized therapy. For instance, the Municon trials suggested the possibility of PET-response guided therapy for esophageal adenocarcinoma (EAC) patients, however there are limitations. New PET parameters such as total lesion glycolysis (TLG) or magnetic resonance imaging (MRI) may provide better response prediction. Furthermore, PET parameters combined with genomic profiling might enhance better treatment selection, prediction, and prognostication. Here, we summarized the current state of understanding and future possibilities.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/17239}
}